Renal Cell Carcinoma
Advertisement
First-line IO + IO therapy is linked to higher costs during the first three months of treatment.
Dr. Dan Joyce discusses key SUO studies on RCC prognostics, personalized medicine, and advancements in treatment strategies.
Dr. Syan highlights advancements in pelvic medicine and reconstructive surgery, and progress in gender-specific challenges.
Dr. Syan shares her vision for the meeting and the lessons or feedback from the past two years that helped shape the program.
Dr. Kaouk explains how a multidisciplinary team should be integrated into the management of RCC.
Dr. Karam explains the main points of emphasis when it comes to small renal masses and surveillance versus surgery.
Serial ctDNA negativity or clearance was linked to improved PFS compared with persistent ctDNA positivity during treatment.
Patients were administered oral belzutifan, 120 mg once daily, in addition to oral cabozantinib, 60 mg once daily.
Radical nephrectomy was associated with a greater decline in postoperative eGFR compared with partial nephrectomy.
The phase 3 ZIRCON trial demonstrated positive results with use of the agent for patients with ccRCC.
The FDA has approved nivo for subcutaneous injection for all solid tumors for which nivo is indicated as a monotherapy.
Dr. Albiges discusses the logistical benefits and considerations of subcutaneous administration of nivolumab for RCC.
Dr. Albiges summarizes the CheckMate 67T study, which evaluated the safety and efficacy of subcutaneous nivolumab for RCC.
Dr. Brian Shuch gives a preview of Urology on the Beach 2025, including his session on molecular imaging agents.
Dr. Shuch shares the key points from his presentation on advancements in molecular imaging for RCC from SUO 2024.
Higher PSMA expression in non-metastatic ccRCC correlates with improved progression-free survival, study shows.
Patient-derived organoids show promise in RCC, enabling personalized therapies and resistance insights.
New data shows patients with nccRCC may benefit from adjuvant therapy at a comparable rate as patients with ccRCC.
Dr. Barragán-Carrillo discusses the current state of RCC treatment, including ICIs, TKIs, and dual ICI regimens.
For the study, researchers identified potential protein biomarkers for diagnosing and prognosticating renal cell carcinoma.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.